抗血小板治疗的个体化时代还有多远要素.ppt

* Tony In a study by Kim et al, individuals with 2 normal genes were considered homozygous extensive metabolizers of PLAVIX, those with 1 normal and 1 abnormal gene were heterozygous extensive metabolizers, and those with 2 abnormal genes were poor metabolizers. Poor metabolizers were found to have a significantly lower antiplatelet effect and heterozygous extensive metabolizers had reduced antiplatelet effect compared to extensive metabolizers. Therefore, polymorphic CYP2C19 genotypes appear to be major determinants of interindividual variability in PLAVIX responsiveness. Kim KA, Park PW